RAC - Charts & Price Action, page-18013

bisantrene is not a clinic-ready drug for solid tumours. just about every other biotech company listed on the ASX has a clinic-ready drug…

an exception for a long while was 1DA (adalda, I think it’s name is)….but even that baby biotech managed to get its drug clinic ready.

can anyone think of another ASX biotech that does not have a clinic-ready drug?

For me, this is the torturous predicament we share holders are in.

Bisantrene looks like it has got a good chance of being better than most other drug options, but it can’t prove this because it isn’t clinic ready!

And it is taking forever to be clinic ready!

does it really have to take another 8 months or whatever to do its toxicology studies and other stuff before it is ready to submit itself for an IND?

I sure hope this long-anticipated strategy makes getting bisantrene 220 clinic-ready as fast as is humanly possible its number one priority.

And is it really true that RAC really has already spent $20m of that cap raise?

how much better it would have been to spend the bulk of that $20m getting Bisantrene 220 over the line, clinic ready months ago.